MitoTEMPO

MitoTEMPO has been studied in 21 papers since 2016: 2 trials and 5 observational studies in people, 7 in animals, 5 in cells, 2 reviews; 6 in the past year. Its furthest trials in people are at phase 2. The newest paper, Sep 14, 2026: “Soluble pathogenic tau transmission to astrocytes drives cellular senescence and neurovascular uncoupling in a model…”.

InterventionPhase 2

21 papers study it13 more mention it37 findingsUpdated

PubChemMeSH

1 new paper in 30 daysSee all 34 papers on MitoTEMPO

At a glance

The findings reach people, from one lab or study; independent labs found the same change in cells. 16 independent labs in 7 countries; 1 trial, none about aging.

“Likewise, Tempol improved Δ%CVCmax compared with Ringer’s (61.40 ± 15.92 vs. 37.02 ± 20.64, p = 0.01), but mitoTempo (44.36 ± 25.91, p = 0.69) did not.”
Relative contributions of mitochondrial and non-mitochondrial oxidative stress in age-related endothelial dysfunctionPhysiology2026doi:10.1152/physiol.2026.41.s1.2297304

1 of its findings points the other way.

Cells: replicated by independent labs. Mice and humans: a single group. Worms or flies: nothing yet.
  • 16 independent labs in 7 countries
  • 1 finding against
  • 1 trial, none about aging
  • Funders: National Natural Science Foundation of China and others
  • 2 of 37 findings with company ties
  • Human trial2
  • Humans5
  • Animals7
  • Cells5

Studies in people

2 studies gave MitoTEMPO to people and measured what changed.

What changedDesignPeopleSource

no change: Has no effect on local heating-induced cutaneous vasodilation

no change: Has no effect on nitric oxide-mediated cutaneous vasodilation

up: Increases non-nitric oxide-mediated cutaneous vasodilation13.95 ± 16.43 versus 4.04 ± 6.14 %CVCmax

Trial15 peopleBoth67 ± 3 yrOlder adults; local heating at 42°CAmerican journal of physiology. Heart and circulatory physiology, May 11, 2026

no change: Has no effect on nitric oxide-dependent cutaneous vasodilation44.36 ± 25.91 vs. 37.02 ± 20.64 %CVCmax, p = 0.69

up: Improves non-nitric oxide-mediated cutaneous vasodilation13.95 ± 16.43 vs. 4.04 ± 6.14 %CVCmax, p < 0.01

Randomized trial6 weeks16 peopleBoth67 ± 3 yrsOlder adults; during the placebo visit, compared with Ringer'sPhysiology, May 1, 2026

What did studies of MitoTEMPO find?

31

Studies of MitoTEMPO measured 31 outcomes; the most studied are cellular senescence (5 studies), non-nitric oxide-mediated cutaneous vasodilation (2) and apoptosis (2).

Cellular senescence

downin animals1downin cells1downin human cells1downin mouse cells1+1

5 studies
  1. MitoTEMPO decreases cellular senescence in human cells.

    “suppression of mitochondrial ROS (mtROS) with mitoTEMPO reduces mtDNA leakage and STING activation, thereby attenuating HUVEC senescence.”

    Cellshuman umbilical vein endothelial cell

    Fat-derived protein worsened signs of vessel aging in mice

    Aging cell

  2. MitoTEMPO decreases cellular senescence in vitro and in vivo.

    “Scavenging mitochondrial ROS with MitoTEMPO reduced tau-induced SASP cytokine and senescence-associated responses in vitro and in vivo”

    Animalsin vitro and in vivo

    Soluble pathogenic tau transmission to astrocytes drives cellular senescence and neurovascular uncoupling in a model of Alzheimer's tauopathy

    bioRxiv : the preprint server for biologyPreprint

  3. MitoTEMPO decreases cellular senescence in BMSCs from ovariectomized rats.

    “Treatment with MitoTEMPO effectively reversed these effects, reinstating lysosomal functionality and suppressing the mitochondrial unfolded protein response (UPRmt).”

    Cellsin BMSCs from ovariectomized rats

    Mitochondria-specific antioxidant MitoTEMPO alleviates senescence of bone marrow mesenchymal stem cells in ovariectomized rats

    Journal of cellular physiology

  4. MitoTEMPO decreases cellular senescence in mouse cells (high-glucose conditions, with or without Mdivi-1).

    “MitoTempo inhibited HG-induced mitochondrial reactive oxygen species and cell senescence with or without Mdivi-1.”

    Cellshigh-glucose conditions, with or without Mdivi-1renal tubular epithelial cell

    Optineurin-mediated mitophagy protects renal tubular epithelial cells against accelerated senescence in diabetic nephropathy

    Cell death & disease

  5. MitoTEMPO decreases cellular senescence in VSMCs.

    “zinc-induced senescence was reduced by inhibition of NF-κB or reduction of mitochondrial ROS with MitoTEMPO”

    Cellsin VSMCs

    Zinc regulates Nox1 expression through a NF-κB and mitochondrial ROS dependent mechanism to induce senescence of vascular smooth muscle cells

    Free radical biology & medicine

More on Cellular senescence

Non-nitric oxide-mediated cutaneous vasodilation

upin humans2

2 studies
  1. MitoTEMPO increases non-nitric oxide-mediated cutaneous vasodilation in humans (local heating at 42°C; compared with Ringer's vehicle) (13.95 ± 16.43 versus 4.04 ± 6.14 %CVCmax).

    “MitoTempo increased the non-NO-mediated component of the response compared with Ringer's (13.95 ± 16.43 vs. 4.04 ± 6.14; P < 0.01)”

    Human triallocal heating at 42°C; compared with Ringer's vehiclecutaneous microvasculature1 mM7 male and 8 femalesn = 15

    Relative contributions of mitochondrial and nonmitochondrial oxidative stress in age-related cutaneous microvascular endothelial dysfunction

    American journal of physiology. Heart and circulatory physiology

  2. MitoTEMPO improves non-nitric oxide-mediated cutaneous vasodilation in humans during the placebo visit, compared with Ringer's (13.95 ± 16.43 vs. 4.04 ± 6.14 %CVCmax, p < 0.01).

    “However, mitoTempo improved non-NO-mediated dilation compared with Ringer’s (13.95 ± 16.43 vs. 4.04 ± 6.14; p < 0.01), whereas Tempol did not (7.16 ± 7.55; p = 0.41).”

    Human trialduring the placebo visit, compared with Ringer'sintradermal microdialysisskin1mMn = 16

    Relative contributions of mitochondrial and non-mitochondrial oxidative stress in age-related endothelial dysfunction

    Physiology

Apoptosis

no changein cells1downin mice1

2 studies
  1. MitoTEMPO showed no clear effect on apoptosis in lysosomal dysfunction-induced apoptosis, tested alongside diphenyleneiodonium.

    “Lysosomal dysfunction-induced apoptosis in chondrocytes was not blocked by antioxidants MitoTempo or Diphenyleneiodonium (DPI)”

    Cellsin lysosomal dysfunction-induced apoptosis, tested alongside diphenyleneiodonium

    Lysosomal dysfunction in osteoarthritis and aged cartilage triggers apoptosis in chondrocytes through BAX mediated release of Cytochrome c

    Osteoarthritis and cartilage

  2. MitoTEMPO inhibits apoptosis in middle-aged Apoe-/-/Sod2+/- mice.

    “decreasing smooth muscle cell apoptosis and matrix degradation”

    Animalsin middle-aged Apoe-/-/Sod2+/- mice

    Attenuated Superoxide Dismutase 2 Activity Induces Atherosclerotic Plaque Instability During Aging in Hyperlipidemic Mice

    Journal of the American Heart Association

More on Apoptosis

Efferocytosis

upin human cells1

1 study
  1. MitoTEMPO improves efferocytosis in THP-1-derived macrophages under FIN-56 treatment.

    “MitoTEMPO reduced mitochondrial ROS and improved efferocytosis”

    Cellsin THP-1-derived macrophages under FIN-56 treatment

    Rapamycin improves efferocytosis and reduces plaques in mice

    International immunopharmacology

Phagocytosis

upin mice1

1 study
  1. MitoTEMPO improves phagocytosis in mice.

    “In a mouse model, MitoTEMPO significantly boosted the phagocytosis of peritoneal macrophages against bacteria.”

    Animalsperitoneal macrophages

    Aging Impairs Macrophage Phagocytosis Through Mitochondrial ROS-Induced Collagen Production

    Aging cell

Nitric oxide-mediated cutaneous vasodilation

no changein humans1

1 study
  1. MitoTEMPO showed no clear effect on nitric oxide-mediated cutaneous vasodilation in humans (local heating at 42°C; compared with Ringer's vehicle).

    “Tempol improved the NO contribution to the response compared with Ringer's (61.40 ± 15.92 vs. 37.02 ± 20.64, P = 0.01), but MitoTempo (P = 0.69) did not.”

    Human triallocal heating at 42°C; compared with Ringer's vehiclecutaneous microvasculature1 mM7 male and 8 femalesn = 15

    Relative contributions of mitochondrial and nonmitochondrial oxidative stress in age-related cutaneous microvascular endothelial dysfunction

    American journal of physiology. Heart and circulatory physiology

Local heating-induced cutaneous vasodilation

no changein humans1

1 study
  1. MitoTEMPO showed no clear effect on local heating-induced cutaneous vasodilation in humans (local heating at 42°C; compared with Ringer's vehicle).

    “Tempol improved the local heating response compared with Ringer's (76.37 ± 18.99 vs. 51.07 ± 23.36, P = 0.02), but MitoTempo (P = 0.25) did not.”

    Human triallocal heating at 42°C; compared with Ringer's vehiclecutaneous microvasculature1 mM7 male and 8 femalesn = 15

    Relative contributions of mitochondrial and nonmitochondrial oxidative stress in age-related cutaneous microvascular endothelial dysfunction

    American journal of physiology. Heart and circulatory physiology

Nitric oxide-dependent cutaneous vasodilation

no changein humans1

1 study
  1. MitoTEMPO showed no clear effect on nitric oxide-dependent cutaneous vasodilation in humans during the placebo visit, compared with Ringer's (44.36 ± 25.91 vs. 37.02 ± 20.64 %CVCmax, p = 0.69).

    “Likewise, Tempol improved Δ%CVCmax compared with Ringer’s (61.40 ± 15.92 vs. 37.02 ± 20.64, p = 0.01), but mitoTempo (44.36 ± 25.91, p = 0.69) did not.”

    Human trialduring the placebo visit, compared with Ringer'sintradermal microdialysisskin1mMn = 16

    Relative contributions of mitochondrial and non-mitochondrial oxidative stress in age-related endothelial dysfunction

    Physiology

TP53

downin rats1

1 study
  1. MitoTEMPO decreases TP53 in trabecular bone region of the proximal tibia of ovariectomized rats.

    “reduced the expression of p53, HSP60, and CLPP in the trabecular bone region of the proximal tibia.”

    Animalsin trabecular bone region of the proximal tibia of ovariectomized ratsbone

    Mitochondria-specific antioxidant MitoTEMPO alleviates senescence of bone marrow mesenchymal stem cells in ovariectomized rats

    Journal of cellular physiology

More on TP53

Trabecular bone loss

downin rats1

1 study
  1. MitoTEMPO decreases trabecular bone loss in ovariectomized rats.

    “MitoTEMPO administration in OVX rats curtailed trabecular bone loss”

    Animalsin ovariectomized rats

    Mitochondria-specific antioxidant MitoTEMPO alleviates senescence of bone marrow mesenchymal stem cells in ovariectomized rats

    Journal of cellular physiology

All 31

Has MitoTEMPO been tested in people?

0 of 1 about aging

Yes: 2 trials and 5 observational studies in people have been published, and 1 trial is registered.

In trials

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 1May 2026: 2Jun 2026: 1Jul 2026: 0Aug 2026: 0Sep 2026: 2Oct 2026: 1Nov 2026: 18 papers in 12 months

See all 34 papers on MitoTEMPO